HUTCHMED Moves Beyond Cancer With China Approvals For Its First In-House Immunology Drug
SYVIK's approvals cover adults with two autoimmune blood disorders whose previous treatments produced insufficient responses.
HUTCHMED, which develops and sells cancer and immunological treatments, secured China approvals Thursday for SYVIK in two autoimmune blood disorders. The company announcement marks its move beyond cancer into commercial immunology through its first internally discovered immunology medicine approved for sale.
Two Approvals After Insufficient Treatment
China's National Medical Products Administration cleared SYVIK, also called sovleplenib, for adults with chronic primary immune thrombocytopenia whose response to at least one previous therapy was insufficient. The condition destroys platelets and reduces their production, increasing the risk of bleeding and bruising.
The second approval covers warm antibody autoimmune hemolytic anemia in adults who responded insufficiently to corticosteroids. That disorder involves antibodies attacking red blood cells.
SYVIK is an oral medicine that blocks spleen tyrosine kinase, or Syk, an enzyme involved in immune-cell activity. HUTCHMED described it as China's first approved novel Syk inhibitor.
Durable Responses Beat Placebo
The platelet-disorder approval drew on a late-stage Chinese trial involving 188 adults, all previously treated with standard therapy. A durable platelet response occurred in 48.4% of SYVIK patients, against zero in the placebo group.
Overall response rates reached 68.3% over weeks 0–12 and 70.6% over weeks 0–24. Placebo rates for those periods were 14.5% and 16.1%, respectively. Results appeared in The Lancet Haematology; HUTCHMED reported tolerable safety and improved quality of life.
In the anemia trial's late-stage portion, the durable response rate during weeks 5–24 was 66% versus 15% on placebo. Overall response rates were 70% and 22%, using a measure requiring hemoglobin of at least 100 grams per liter and an increase of at least 20 grams per liter without rescue treatment.
HUTCHMED reported no treatment-related deaths or treatment discontinuations in the SYVIK group. Mid-stage findings appeared in The Lancet Haematology, and late-stage results were presented at the European Hematology Association's 2026 Congress.
Worldwide Rights Stay With HUTCHMED
HUTCHMED's established drug business includes savolitinib, fruquintinib and surufatinib, sold in China as Orpathys, Elunate and Sulanda. Partner Takeda sells fruquintinib outside China as Fruzaqla, while AstraZeneca commercializes savolitinib.
Sovleplenib received FDA orphan-drug designation for primary immune thrombocytopenia and autoimmune hemolytic anemia in October 2026. HUTCHMED retains worldwide rights and said it is evaluating options for global development.
Johnny Cheng, HUTCHMED's acting chief executive and chief financial officer, said: "We are committed to making this new targeted treatment option accessible to patients across China".
HUTCHMED's market value was $2.4 billion at Wednesday's close.
Sources
- Form 6-K — Simultaneous approvals in two underserved autoimmune indications supported by positive ESLIM-01 trial in ITP and ESLIM-02 trial in wAIHA — — Expands HUTCHMED’s commercial portfolio into imm — SEC EDGAR
- HUTCHMED (AIM:HCM) Stock Looks Overvalued On Current Earnings — Yahoo Finance
- HUTCHMED Announces China NMPA Approval of SYVIK® — globenewswire.com
- HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented — globenewswire.com